FeldmanRDCampbellNLarochelleP, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ1999;161(Suppl 12):S1-S17.
2.
RabiDMMcBrienKASapir-PichhadzeR, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment and treatment of hypertension in adults and children. Can J Cardiol2020;36(5):596-624.
3.
Al HamarnehYNHemmelgarnBRHassanIJonesCATsuyukiRT.The effectiveness of pharmacist interventions on cardiovascular risk in adult patients with type 2 diabetes: the multicentre randomized controlled RxEACH trial. Can J Diabetes2017;41(6):580-6.
4.
SantschiVChioleroAParadisGColosimoALBurnandB.Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care2012;35(12):2706-17.
5.
TsuyukiRTAl HamarnehYNJonesCAHemmelgarnBR.The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol2016;67(24):2846-54.
6.
TsuyukiRTHouleSKCharroisTL, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Circulation2015;132(2):93-100.
7.
SantschiVTsuyukiRTParadisG.Evidence for pharmacist care in the management of hypertension. Can Pharm J (Ott)2015;148(1):13-6.
8.
CampbellNRCPoirierLTremblayGLindsayPReidDTobeSW. Canadian Hypertension education program: the science supporting new 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation. Can J Cardiol2011;27(4):407-14.
9.
TobariHArimotoTShimojoN, et al. Physician-pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. Am J Hypertens2010;23(10):1144-52.
10.
McLeanDLMcAlisterFAJohnsonJA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: Study of Cardiovascular Risk Intervention by Pharmacists–Hypertension (SCRIP-HTN). Arch Intern Med2008;168(21):2355-61.
11.
CarterBLDoucetteWRFranciscusCLArderyGKluesnerKMChrischillesEA.Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. Pharmacotherapy2010;30(3):228-35.
12.
HouleSKDPadwalRPoirierLTsuyukiRT. The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2015;148(4):180-6.
13.
HouleSKPadwalRPoirierLTsuyukiRT.The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2014;147(4):203-8.
14.
HouleSKPadwalRTsuyukiRT.The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2013;146(3):146-50.
15.
Al HamarnehYNHouleSKDPadwalRTsuyukiRT.Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for pharmacists: an update. Can Pharm J (Ott)2016;149(6):337-44.
16.
HiremathSSapir-PichhadzeRNakhlaM, et al. Hypertension Canada’s 2020 evidence review and guidelines for the management of resistant hypertension. Can J Cardiol2020;36(5):625-34.
17.
WilliamsBMacDonaldTMMorantS, et al. Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet2015;386(10008):2059-68.
18.
WilliamsBMacDonaldTMMorantSV, et al. Endocrine and haemodynamic changes in resistant hypertension and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol2018;6(6):464-75.
19.
KriegerEMDragerLFGiorgiDMA, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension. Hypertension2018;71(4): 681-90.
20.
LuYChenRCaiJHuangZYuanH.The management of hypertension in women planning for pregnancy. Br Med Bull2018;128(1):75-84.
21.
BartschEMedcalfKEParkALRayJG; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ2016;353:i1753-i.
22.
BulloMTschumiSBucherBSBianchettiMGSimonettiGD.Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension2012;60(2):444-50.
23.
ButaliaSAudibertFCoteAM, et al. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol2018;34(5):526-31.
24.
BeckmannMMWidmerTBoltonE.Does preconception care work?Aust N Z J Obstet Gynaecol2014;54(6):510-4.
25.
DavenportMHRuchatSMPoitrasVJ, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. Br J Sports Med2018;52(21):1367-75.
26.
HanssonLZanchettiACarruthersSG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62.
27.
ZhengSLRoddickAJ.Meta-analysis of aspirin for primary prevention of cardiovascular events—reply. JAMA2019;321(22):2244-5.
28.
MahmoudANGadMMElgendyAYElgendyIYBavryAA.Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J2019;40(7):607-17.
29.
McNeilJJWolfeRWoodsRL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med2018;379(16):1509-18.
30.
AimoADe CaterinaR.Aspirin for primary prevention of cardiovascular disease: advice for a decisional strategy based on risk stratification. Anatol J Cardiol2020;23(2):70-8.
31.
WoodAMKaptogeSButterworthAS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet2018;391(10129):1513-23.
32.
RoereckeMKaczorowskiJTobeSWGmelGHasanOSMRehmJ.The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health2017;2(2):e108-e20.
33.
CutlerRLTorres-RoblesAWiecekE, et al. Pharmacist-led medication non-adherence intervention: reducing the economic burden placed on the Australian health care system. Patient Prefer Adherence2019;13:853-62.
34.
BurnierMEganBM.Adherence in hypertension. Circ Res2019;124(7): 1124-40.
35.
DurandHHayesPMorrisseyEC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens2017;35(12):2346-57.
36.
HameedMADasguptaI.Medication adherence and treatment-resistant hypertension: a review. Drugs Context2019;8:212560.
37.
RenYYangHBrowningCThomasSLiuM.Therapeutic effects of motivational interviewing on blood pressure control: a meta-analysis of randomized controlled trials. Int J Cardiol2014;172(2):509-11.
38.
KhanNBellABergA, et al. A call to action to implement prescribing authority to pharmacists for hypertension management. Can Pharm J (Ott)2019;152(5):285-7.
39.
Al HamarnehYNJohnstonKMarraCATsuyukiRT.Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study. Can Pharm J (Ott)2019;152(4):257-66.
40.
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015;373(22):2103-16.
41.
Al HamarnehYNSauriolLTsuyukiRT.After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study. BMJ Open2015; 5(8):e008152.
42.
MacCallumLConsiglioGMacKeiganLDolovichL.Uptake of community pharmacist-delivered MedsCheck diabetes medication review service in Ontario between 2010 and 2014. Can J Diabetes2017;41(3):253-8.
